Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3-MUC1 bispecific antibody + autologous T cells
- Development stage
- Unknown
- Lead developer
- Benhealth Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
CD3-MUC1 bispecific antibody + autologous T cells is a combination immunotherapy being developed by Benhealth Biopharmaceutical for the treatment of lung cancer. This therapeutic approach utilizes a bispecific antibody designed to simultaneously target the CD3 receptor on T cells and the Mucin 1 (MUC1) antigen, which is frequently overexpressed in various cancers, including lung cancer. By binding to both targets, the bispecific antibody facilitates immune-cell redirection, bringing T cells into close proximity with MUC1-expressing tumor cells to promote targeted cytotoxicity. This antibody is administered in conjunction with autologous T cells, which are harvested from the patient and potentially expanded or activated ex vivo before reinfusion, to enhance the overall anti-tumor immune response. The program is currently in clinical development in collaboration with Shenzhen People's Hospital.
- Other names
- CD3-MUC1 bispecific antibody + autologous T cellsCD3/MUC1 bispecific antibody + autologous T cells
02
Targets
CD3 (T-cell surface glycoprotein CD3)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on CD3-MUC1 bispecific antibody + autologous T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3-MUC1 bispecific antibody + autologous T cells.